Log In
Print this Print this

Liraglutide 3 mg (Saxenda) (NN8022)

  Manage Alerts
Collapse Summary General Information
Company Novo Nordisk A/S
DescriptionHuman glucagon-like peptide-1 (GLP-1) analog
Molecular Target Glucagon-like peptide-1 (GLP-1)
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentMarketed
Standard IndicationObesity
Indication DetailsTreat obesity
Regulatory Designation U.S. - Standard Review (Treat obesity);
EU - Standard Review (Treat obesity)

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today